# Fate Therapeutics, Inc. (FATE) stock: price and valuation

URL: https://funkfolio.com/stock/FATE

> Fate Therapeutics, Inc. (FATE) trades at $1.04, is worth $126.38M and scores 25/100. Valuation history, financials and signals.

---

## Fate Therapeutics, Inc. (FATE)

Fate Therapeutics, Inc. (FATE) is a healthcare company (biotechnology) based in the United States. The share price is $1.04, down 8.89% on the day, which values the company at $126.38M. Price as of 17 Nov 2026, 17:33 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $1.04 −8.89% today
- **Market value:** $126.38M
- **Funk Score:** 25/100
- **Against its own history:** Well below its usual price usual price $1.75
- **200-week average:** $2.86 64% below
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 17:33 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Fate Therapeutics, Inc. in more detail

FATE trades at -1.1× next year's expected earnings, 26.6× sales. Measured against its own history, the price is 41% below what its usual multiples would imply ($1.75) — well below its usual price. It sits 64% below its 200-week average of $2.86.

Over the last five fiscal years Fate Therapeutics, Inc. has compounded revenue -26.7% a year. Its Funk Score is 25 out of 100 (financial strength 3.8, profitability 0.0, growth 1.3, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

### Fate Therapeutics, Inc. (FATE): questions and answers

**What is Fate Therapeutics, Inc.'s market cap?**

Fate Therapeutics, Inc. is valued at $126.38M at a share price of $1.04.

**Is FATE overvalued or undervalued?**

Against its own history, FATE is well below its usual price: the price is 41% below the $1.75 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is FATE above its 200-week moving average?**

No. FATE is 63.6% below its 200-week average of $2.86. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Fate Therapeutics, Inc. growing?**

Over the last five fiscal years Fate Therapeutics, Inc.'s revenue grew -26.7% a year; over ten years revenue grew 10.6% a year.

**Does FATE pay a dividend?**

Fate Therapeutics, Inc. does not currently pay a regular dividend.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Fate Therapeutics, Inc. (FATE) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/FATE

Underlying data: Yahoo Finance; company filings with the SEC.
